Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
Induction chemotherapy provides an excellent model for evaluation of potential predictive factors. We studied expression of SBR grade, estrogen (ER) and progesterone (PR) receptors, HER2, Ki67 and P53 on core biopsies before and after chemotherapy in a series of 115 patients, who received anthracycline-based induction chemotherapy for primary breast cancer. HER2 overexpression independently predicted response to neoadjuvant anthracycline-based chemotherapy. Patients with HER2-positive status are 4.54 times more likely to have a pathological complete response than those with negative status (p<0.005). HER2, ER and PR status were stable during treatment. P53 and Ki67 significantly increased after treatment (p<0.005 and p<0.0005). SBR grade, proliferation markers, ER evaluated before and after treatment predicted disease-free survival (DFS) in univariate analysis.
Department of Pathology, Centre Jean Perrin, BP 392, 63011 Clermont-Ferrand Cédex, France. fpenault@cjp.u-clermont1.fr
Frédérique
F
Penault-Llorca
Anne
A
Cayre
Florence
F
Bouchet Mishellany
Sophie
S
Amat
Viviane
V
Feillel
Guillaume
G
Le Bouedec
Jean-Pierre
JP
Ferrière
Monique
M
De Latour
Philippe
P
Chollet
D000782:Aneuploidy; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008207:Lymphatic Metastasis; D008593:Menopause; D008875:Middle Aged; D008938:Mitosis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016196:S Phase; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D015251:Epirubicin; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C027260:pirarubicin